This study developed a novel silica-coated magnetic nanoparticle (Fe3O4@SiO2@Cu BTC) based on a metal-organic framework (MOF) for targeted anticancer medication delivery. Using a co-precipitation method, the Fe3O4@SiO2 core was coated with Cu(OH)2 shell, which was then
More
This study developed a novel silica-coated magnetic nanoparticle (Fe3O4@SiO2@Cu BTC) based on a metal-organic framework (MOF) for targeted anticancer medication delivery. Using a co-precipitation method, the Fe3O4@SiO2 core was coated with Cu(OH)2 shell, which was then converted to CuBTC in a hydroethanolic mixture. Finally, a post-synthetic approach was used to manufacture a 3-(mercaptopropyl) trimethoxysilane functionalized Fe3O4@SiO2@Cu BTC nanocomposite. The resulting material is characterized using SEM-EDX, TEM, VSM, XRD, TGA, BET, UV–Vis, and FTIR techniques. TEM and SEM micrographs confirmed the core-shell structure. The resulting nanocomposite has high thermal stability, according to TGA findings. Because of their great biocompatibility and drug loading capability, coated Fe3O4@SiO2@Cu BTC nanoparticles might be perfect for drug delivery. Capecitabine (CAP), an anticancer medication, was successfully dispersed through MOF pores. The acquired data revealed that 91 percent of the CAP was adsorbed on the constructed framework, and that the release of capecitabine in PBS buffer solution (pH 5.7) at 37 °C took up to 60 hours to complete. The findings show that nano-sized MOFs-based magnetic NPs with high drug loading and acceptable biocompatibility are viable options for targeted drug delivery.
Manuscript profile
